BR112013025777A2 - imidazopiridazinas como inibidores da quinase akt - Google Patents

imidazopiridazinas como inibidores da quinase akt

Info

Publication number
BR112013025777A2
BR112013025777A2 BR112013025777A BR112013025777A BR112013025777A2 BR 112013025777 A2 BR112013025777 A2 BR 112013025777A2 BR 112013025777 A BR112013025777 A BR 112013025777A BR 112013025777 A BR112013025777 A BR 112013025777A BR 112013025777 A2 BR112013025777 A2 BR 112013025777A2
Authority
BR
Brazil
Prior art keywords
imidazopyridazines
kinase inhibitors
akt kinase
formula
production
Prior art date
Application number
BR112013025777A
Other languages
English (en)
Inventor
Andrea Hägebarth
Hans Briem
Hartmut Rehwinkel
Lars Bärfacker
Oliver Politz
Roland Neuhaus
Stuart Ince
Ulf Bömer
William Johnston Scott
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of BR112013025777A2 publication Critical patent/BR112013025777A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

abstract imidazopyridazines of formula (i) a process for their production and the use thereof. **************************************************** tradução do resumo resumo patente de invenção: "imidazopiridazinas como inibidores da quinase akt". imidazopiridazinas de fórmula (i) um processo para sua produção e uso das mesmas.
BR112013025777A 2011-04-07 2012-04-05 imidazopiridazinas como inibidores da quinase akt BR112013025777A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112013025777A2 true BR112013025777A2 (pt) 2016-12-20

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025777A BR112013025777A2 (pt) 2011-04-07 2012-04-05 imidazopiridazinas como inibidores da quinase akt

Country Status (42)

Country Link
US (2) US9206185B2 (pt)
EP (1) EP2694510B1 (pt)
JP (1) JP5906303B2 (pt)
KR (1) KR20140022057A (pt)
CN (1) CN103596957B (pt)
AP (1) AP3597A (pt)
AR (1) AR087148A1 (pt)
AU (1) AU2012238589B2 (pt)
BR (1) BR112013025777A2 (pt)
CA (1) CA2832374A1 (pt)
CL (1) CL2013002878A1 (pt)
CO (1) CO6862145A2 (pt)
CR (1) CR20130515A (pt)
CU (1) CU24263B1 (pt)
CY (1) CY1117163T1 (pt)
DK (1) DK2694510T3 (pt)
DO (1) DOP2013000226A (pt)
EA (1) EA024890B1 (pt)
EC (1) ECSP13013008A (pt)
ES (1) ES2558780T3 (pt)
GT (1) GT201300238A (pt)
HR (1) HRP20160011T1 (pt)
HU (1) HUE026323T2 (pt)
IL (1) IL228567A0 (pt)
JO (1) JO3068B1 (pt)
MA (1) MA35016B1 (pt)
ME (1) ME02316B (pt)
MX (1) MX336865B (pt)
NI (1) NI201300105A (pt)
PE (1) PE20141380A1 (pt)
PL (1) PL2694510T3 (pt)
PT (1) PT2694510E (pt)
RS (1) RS54480B1 (pt)
SG (1) SG193631A1 (pt)
SI (1) SI2694510T1 (pt)
SM (1) SMT201600001B (pt)
TN (1) TN2013000400A1 (pt)
TW (1) TWI535719B (pt)
UA (1) UA111739C2 (pt)
UY (1) UY34006A (pt)
WO (1) WO2012136776A1 (pt)
ZA (1) ZA201307223B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
TR201903981T4 (tr) 2008-06-16 2019-04-22 Univ Ohio State Res Found Kanser tedavisi için bileşikler.
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
MA35016B1 (fr) * 2011-04-07 2014-04-03 Bayer Ip Gmbh Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
US9370517B2 (en) * 2012-01-10 2016-06-21 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
CN107970214A (zh) * 2012-11-30 2018-05-01 葛兰素史克公司 新型药物组合物
US10022356B2 (en) * 2013-03-05 2018-07-17 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
WO2014153001A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Combination therapy for treating cancer
EP3092242A1 (en) * 2014-01-09 2016-11-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2018098411A1 (en) * 2016-11-28 2018-05-31 Bristol-Myers Squibb Company Gsk-3 inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2002002582A0 (en) 1999-12-23 2002-09-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
WO2001074815A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
CA2407573C (en) 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004096131A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
DE602004010680T2 (de) 2003-07-30 2009-01-02 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Substituierte imidazopyrimidine zur prävention und behandlung von krebs
EP1737843B1 (en) 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
JP2008510741A (ja) 2004-08-24 2008-04-10 ビーエーエスエフ ソシエタス・ヨーロピア イオン液体を製造するための出発化合物としてのイミダゾリウム−メチルスルファイト
EP1827436A4 (en) 2004-12-15 2011-08-10 Merck Sharp & Dohme ACTIVITY INHIBITORS AKT
EP1902056A2 (en) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
NZ563423A (en) 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
DE602008005894D1 (de) 2007-08-14 2011-05-12 Bayer Schering Pharma Ag Kondensierte imidazole zur krebsbehandlung
RS52559B (en) 2007-08-14 2013-04-30 Bayer Intellectual Property Gmbh FUSIONED BICYCLIC PYRIMIDINES
AU2008345688A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-b] pyridazine compounds as modulators of liver X receptors
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
EP2299825B1 (en) 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
US20110288090A1 (en) 2009-02-02 2011-11-24 Armstrong Donna J Inhibitors of AKT Activity
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
US8546376B2 (en) 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
US8975265B2 (en) 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
MA35016B1 (fr) * 2011-04-07 2014-04-03 Bayer Ip Gmbh Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt

Also Published As

Publication number Publication date
US20150368250A1 (en) 2015-12-24
DK2694510T3 (en) 2016-01-18
MX2013011699A (es) 2014-01-31
CU24263B1 (es) 2017-07-04
PL2694510T3 (pl) 2016-03-31
JP2014510127A (ja) 2014-04-24
JP5906303B2 (ja) 2016-04-20
UY34006A (es) 2012-10-31
WO2012136776A1 (en) 2012-10-11
CL2013002878A1 (es) 2014-05-02
AP3597A (en) 2016-02-19
SI2694510T1 (sl) 2016-02-29
IL228567A0 (en) 2013-12-31
SMT201600001B (it) 2016-02-25
UA111739C2 (uk) 2016-06-10
CN103596957A (zh) 2014-02-19
AU2012238589B2 (en) 2017-02-16
AU2012238589A1 (en) 2013-11-07
MA35016B1 (fr) 2014-04-03
CR20130515A (es) 2013-12-04
US20140113901A1 (en) 2014-04-24
TW201245204A (en) 2012-11-16
TWI535719B (zh) 2016-06-01
TN2013000400A1 (en) 2015-03-30
SG193631A1 (en) 2013-11-29
CY1117163T1 (el) 2017-04-05
CU20130135A7 (es) 2014-02-28
HRP20160011T1 (hr) 2016-02-12
EA201301130A1 (ru) 2014-07-30
CN103596957B (zh) 2016-12-07
MX336865B (es) 2016-02-04
JO3068B1 (ar) 2017-03-15
NZ616270A (en) 2015-09-25
ES2558780T3 (es) 2016-02-08
EP2694510B1 (en) 2015-10-14
KR20140022057A (ko) 2014-02-21
HUE026323T2 (en) 2016-05-30
CA2832374A1 (en) 2012-10-11
US9206185B2 (en) 2015-12-08
US9604989B2 (en) 2017-03-28
AP2013007215A0 (en) 2013-10-31
PT2694510E (pt) 2016-02-08
NI201300105A (es) 2014-07-14
ECSP13013008A (es) 2013-12-31
EA024890B1 (ru) 2016-10-31
AR087148A1 (es) 2014-02-26
CO6862145A2 (es) 2014-02-10
ME02316B (me) 2016-06-20
GT201300238A (es) 2015-04-06
DOP2013000226A (es) 2013-11-15
PE20141380A1 (es) 2014-10-18
RS54480B1 (en) 2016-06-30
EP2694510A1 (en) 2014-02-12
ZA201307223B (en) 2014-12-23

Similar Documents

Publication Publication Date Title
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO6640285A2 (es) 5-alquinil-pirimidinas
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112013015005A2 (pt) corpo moldado contendo lignocelulose em multicamadas, processo para sua produção, e, uso do corpo moldado
BR112014029993A2 (pt) compósito plano, processo para a produção de um compósito plano, processo para a produção de um recipiente que envolve um interior, recipiente e uso de um compósito ou de um recipiente
BR112013022930A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica
BR112014030949A2 (pt) "composição, processo para o tratamento cosmético e uso de uma composição"
UY34273A (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación
CU20130044A7 (es) Proceso para la preparación de inhibidores de pan-cdk de fórmula (i), e intermediarios de la preparación
UY34320A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos.
BR112013027219A2 (pt) composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
BR112014030955A2 (pt) "composição, processo para o tratamento cosmético e uso de uma composição"
UY4464U (es) Equipamiento modular para la producción de alcohol hidratado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI